Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Cancer Res. 2017 May 16;77(13):3619–3631. doi: 10.1158/0008-5472.CAN-16-2784

Figure 1. BCL1 lymphoma generates a profoundly immunosuppressive tumor microenvironment.

Figure 1

(A) WT BALB/c mice were implanted with BCL1 lymphoma cells 1 week prior to transfer of target (T) hCD20Tg B cells and non-Tg non-target (NT) B-cells. Mice were then treated with Ritm2a 2 days later and spleens harvested the following day and assessed for T:NT ratio (n=5-6, Wilcoxon test). (B) WT BALB/c mice were implanted with BCL1 lymphoma and the number of tumor cells in the spleen quantitated by flow cytometry. (C) Correlation between spleen weight and tumor percentage in the spleen. (D) Fold change in macrophage FcγR expression and (E) A:I ratio on splenic macrophages, monocytes and neutrophils (n=12, student’s t test). (F) Adoptive transfer as in A, in BCL1 lymphoma bearing WT vs FcγRII KO BALB/c recipient mice with hCD20TgxFcγRII KO B cells as target (T) and FcγRIIKO B cells as non-targets (NT).